Free Trial

argenx (ARGX) Stock Price, News & Analysis

argenx logo
$579.77 -7.84 (-1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$639.09 +59.32 (+10.23%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About argenx Stock (NASDAQ:ARGX)

Key Stats

Today's Range
$578.69
$595.02
50-Day Range
$532.27
$656.65
52-Week Range
$359.37
$678.21
Volume
339,403 shs
Average Volume
325,549 shs
Market Capitalization
$35.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$698.11
Consensus Rating
Buy

Company Overview

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

ARGX MarketRank™: 

argenx scored higher than 67% of companies evaluated by MarketBeat, and ranked 331st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    argenx has received a consensus rating of Buy. The company's average rating score is 3.04, and is based on 20 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    argenx has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about argenx's stock forecast and price target.
  • Earnings Growth

    Earnings for argenx are expected to grow by 246.65% in the coming year, from $3.13 to $10.85 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of argenx is -658.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of argenx is -658.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    argenx has a P/B Ratio of 8.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about argenx's valuation and earnings.
  • Percentage of Shares Shorted

    3.75% of the outstanding shares of argenx have been sold short.
  • Short Interest Ratio / Days to Cover

    argenx has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in argenx has recently increased by 0.88%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    argenx does not currently pay a dividend.

  • Dividend Growth

    argenx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.75% of the outstanding shares of argenx have been sold short.
  • Short Interest Ratio / Days to Cover

    argenx has a short interest ratio ("days to cover") of 6.1.
  • Change versus previous month

    Short interest in argenx has recently increased by 0.88%, indicating that investor sentiment is decreasing.
  • News Sentiment

    argenx has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for argenx this week, compared to 10 articles on an average week.
  • Search Interest

    6 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added argenx to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, argenx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.43% of the stock of argenx is held by insiders.

  • Percentage Held by Institutions

    60.32% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about argenx's insider trading history.
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock News Headlines

Brokerages Set argenx SE (NASDAQ:ARGX) Target Price at $698.11
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

ARGX Stock Analysis - Frequently Asked Questions

argenx's stock was trading at $615.00 at the start of the year. Since then, ARGX shares have decreased by 5.7% and is now trading at $579.77.
View the best growth stocks for 2025 here
.

argenx SE (NASDAQ:ARGX) posted its earnings results on Thursday, May, 8th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.26. The firm earned $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative net margin of 2.11% and a negative trailing twelve-month return on equity of 1.45%.
Read the conference call transcript
.

argenx (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

argenx's top institutional shareholders include Price T Rowe Associates Inc. MD (8.82%), Wellington Management Group LLP (0.67%), Invesco Ltd. (0.63%) and Lord Abbett & CO. LLC (0.45%).

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that argenx investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE).

Company Calendar

Last Earnings
5/08/2025
Today
5/27/2025
Next Earnings (Estimated)
7/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
650
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$698.11
High Stock Price Target
$1,065.00
Low Stock Price Target
$500.00
Potential Upside/Downside
+20.4%
Consensus Rating
Buy
Rating Score (0-4)
3.04
Research Coverage
23 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
185.23
P/E Growth
N/A
Net Income
-$295.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.58 billion
Price / Cash Flow
N/A
Book Value
$69.22 per share
Price / Book
8.38

Miscellaneous

Free Float
59,285,000
Market Cap
$35.40 billion
Optionable
Optionable
Beta
0.57
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ARGX) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners